3-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine
• 化学式: C₈H₈F₃N
• 分子量: 175.15
• InChiKey: FNCJBRSOXOEDTB-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20140309231A1

  公开（公告）日：2014-10-16

  A nitrogen-containing heterocyclic compound represented by formula (I-A): (wherein R 1A represents lower alkyl which may be substituted with lower alkoxy, R 3A represents lower alkyl substituted with fluorine atom(s), and R 4A represents an optionally substituted aromatic heterocyclic group) or the like, or a pharmaceutically acceptable salt thereof; and the like, are provided.

  提供了一种由公式(I-A)表示的含氮杂环化合物：（其中R1A表示可以用低烷氧基取代的低烷基，R3A表示用氟原子取代的低烷基，R4A表示可选地取代的芳香杂环基）或其药学上可接受的盐等。
• BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20190047990A1

  公开（公告）日：2019-02-14

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—R z and N; R 1 is selected from: -(Alk 1 ) t -Cyc 1 ; wherein t is 0 or 1; Optionally substituted C 1-6 acyclic hydrocarbon groups R 2 is selected from hydrogen; halogen; and C 1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R 3 is hydrogen or a group L 1 -R 7 ; R 4 is selected from hydrogen; methoxy; and optionally substituted C 1-3 alkyl; and R 4a is selected from hydrogen and a C 1-3 alkyl group; wherein R z , Alk 1 , Cyc 1 , L 1 and R 7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.